Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SPRITAM vs DIPHENYLAN SODIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Spritam is a levetiracetam formulation; levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A) to modulate neurotransmitter release, reducing neuronal excitability.
Phenytoin, the active component, stabilizes neuronal membranes by promoting sodium efflux and inhibiting sodium influx, thereby limiting the spread of seizure activity. It also reduces voltage-gated sodium channel activity.
Adjunctive therapy for partial-onset seizures,Myoclonic seizures in JME,Primary generalized tonic-clonic seizures
FDA-approved: Generalized tonic-clonic seizures, complex partial seizures,Off-label: Prevention of seizures during neurosurgery, status epilepticus (parenteral), trigeminal neuralgia
SPRITAM is not a standard formulation; levetiracetam immediate-release: 500 mg PO BID, titrated to 1000 mg PO BID (max 1500 mg PO BID). For extended-release (Keppra XR): 1000 mg PO once daily, titrated to 2000 mg PO once daily.
100 mg orally every 8 hours
Terminal half-life: 6–8 hours; clinical context: requires twice-daily dosing for stable serum concentrations
22 hours (range 10-34 hours); prolonged in hepatic impairment or with CYP inhibitors; correlates with time to steady state (~5 days).
Hydrolysis by esterases in blood and tissues to carboxylic acid metabolite (ucb L057); not CYP450 dependent.
Primarily hepatic metabolism via CYP2C9 and CYP2C19 isoenzymes, with saturation kinetics at therapeutic concentrations. Major metabolite: 5-(p-hydroxyphenyl)-5-phenylhydantoin (HPPH).
Renal: 66% unchanged; hepatic metabolism: 24% (inactive metabolites); fecal: negligible (<1%)
Primarily hepatic metabolism via CYP450; <5% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 20-30% of metabolites.
<10% bound; primarily to albumin (minimal binding)
90-95% mainly to albumin; displaces and is displaced by other highly protein-bound drugs.
0.7–1.1 L/kg; approximates total body water, indicating extensive distribution into tissues
0.6-0.8 L/kg; larger in neonates (up to 1.2 L/kg); indicates extensive tissue binding, particularly in brain and adipose.
Oral immediate-release: 100%; oral extended-release: approximately 100% relative to immediate-release
Oral: 85-95% (capsules and tablets); intramuscular: 70-80% due to precipitation at injection site.
Cr Cl >80 m L/min: 500-1500 mg BID (IR) or 1000-2000 mg once daily (XR); Cr Cl 50-80: 500-1000 mg BID (IR) or 1000-2000 mg once daily (XR); Cr Cl 30-50: 250-750 mg BID (IR) or 500-1500 mg once daily (XR); Cr Cl <30: 250-500 mg BID (IR) or 500-1000 mg once daily (XR); ESRD on dialysis: 500-1000 mg once daily (IR) with supplemental dose after dialysis.
No adjustment required for GFR >30 m L/min; for GFR 10-30 m L/min, administer every 12-24 hours; for GFR <10 m L/min, administer every 24 hours with monitoring of serum levels
Mild to moderate hepatic impairment (Child-Pugh A or B): no dose adjustment required; severe hepatic impairment (Child-Pugh C): use with caution; no specific dose reduction recommended, but monitor for adverse effects.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25-50%; Child-Pugh Class C: avoid use or reduce dose by 50-75% with close monitoring
For immediate-release: age 1 month to <6 months: 7 mg/kg/dose BID initially, titrate to 21 mg/kg/dose BID; age 6 months to <4 years: 10 mg/kg/dose BID initially, titrate to 25 mg/kg/dose BID; age 4 to <16 years: 10 mg/kg/dose BID initially, titrate up to 30 mg/kg/dose BID (max 1500 mg/day). For extended-release: only for ≥12 years: 1000 mg once daily initially, titrate to 2000 mg once daily.
5-7 mg/kg/day orally divided every 8-12 hours, not to exceed 300 mg/day
Consider age-related renal impairment; adjust dose based on Cr Cl per renal adjustment. Start at lower end of dosing range; monitor for sedation, dizziness, and falls.
Initial dose of 50 mg orally every 8 hours, titrate slowly based on response and tolerability; monitor renal function and serum levels
No FDA black box warning.
Intravenous administration: Risk of serious cardiovascular reactions including hypotension and cardiac arrest, especially in elderly patients and those with underlying cardiac disease. Rate of infusion should not exceed 50 mg/min in adults.
Behavioral abnormalities (psychosis, aggression, suicidal ideation),Somnolence and fatigue,Dermatological reactions (e.g., Stevens-Johnson syndrome),Hematologic abnormalities,Withdrawal seizures on abrupt discontinuation
1. Cardiovascular risk with IV administration. 2. Suicide risk and behavioral changes. 3. Hepatotoxicity (monitor LFTs). 4. Hematologic effects (agranulocytosis, thrombocytopenia). 5. Lymphadenopathy. 6. Teratogenicity (fetal hydantoin syndrome). 7. Hyperglycemia. 8. Withdrawal seizures. 9. Dermatologic reactions (Stevens-Johnson syndrome). 10. Osteoporosis with chronic use.
Hypersensitivity to levetiracetam or any component of Spritam
Absolute: Hypersensitivity to phenytoin, hydantoins, or any component; sinus bradycardia, sinoatrial block, second- or third-degree AV block, or Stokes-Adams syndrome (IV formulation); concurrent use with delavirdine. Relative: Pregnancy (especially first trimester; weigh risk vs benefit), hepatic impairment, alcoholism, porphyria.
No significant food interactions. SPRITAM can be taken with or without food. A high-fat meal may slightly delay absorption but does not affect overall exposure. Avoid grapefruit juice? Not required; no known interaction with grapefruit. Alcohol may potentiate CNS depression and should be avoided.
Avoid grapefruit and grapefruit juice as it inhibits CYP metabolism and can increase phenytoin levels. Enteral feeding formulas may reduce absorption; administer phenytoin 1-2 hours before or after enteral feeds. High doses of folic acid may decrease phenytoin levels. Chronic use can lead to vitamin D and folate deficiency; consider supplementation if indicated. Alcohol consumption should be minimized—acute intake can increase levels while chronic use decreases them.
Spritam (levetiracetam) is classified as Pregnancy Category C. In the first trimester, there is an increased risk of major congenital malformations, including neural tube defects, when used in polytherapy, but monotherapy may have a lower risk. Data from human pregnancy registries suggest a risk of major birth defects of 1.5-2.4% with monotherapy, compared to a baseline risk of 2-4%. In the second and third trimesters, exposure may lead to decreased fetal growth and transient neonatal effects such as sedation, withdrawal symptoms, and hypotonia. Levetiracetam is not highly protein-bound and crosses the placenta with a cord-to-maternal plasma ratio close to 1.
First trimester: Increased risk of major congenital malformations including neural tube defects, cleft palate, and congenital heart defects. Second and third trimesters: Risks of bleeding disorders in the newborn due to vitamin K deficiency, and potential for neonatal withdrawal and growth restriction.
Levetiracetam is excreted into human breast milk with a milk-to-plasma (M/P) ratio of approximately 1.0. Relative infant dose is about 1-3% of maternal weight-adjusted dose, which is considered low. Limited data suggest no adverse effects on infant development. However, due to potential for lethargy and poor feeding, breastfeeding should be monitored. The benefits of breastfeeding likely outweigh risks for most infants.
Diphenhydramine is excreted into breast milk in small amounts; reported M/P ratio is approximately 0.5 to 1.0. In infants, risks of drowsiness, irritability, and paradoxical excitation. Generally considered compatible with breastfeeding, but monitor infant for adverse effects.
Pregnancy can alter levetiracetam pharmacokinetics, with increased clearance and reduced serum concentrations in the second and third trimesters. Dose adjustments may be necessary to maintain seizure control. Therapeutic drug monitoring is recommended, with target trough levels at the lower end of the therapeutic range (12-46 mcg/m L) to minimize fetal exposure while ensuring efficacy. Postpartum, clearance returns to baseline, and doses should be reduced accordingly.
No specific dose adjustments are typically required. However, due to increased volume of distribution and metabolism in pregnancy, therapeutic levels may need monitoring. Initial dose adjustments are not recommended, but consider dose increases if clinical response is inadequate.
SPRITAM (levetiracetam) is a racetam anticonvulsant with a unique mechanism of action (SV2A binding). It exhibits linear pharmacokinetics with rapid oral absorption. No therapeutic drug monitoring required due to wide therapeutic index. Adjust dose in renal impairment (Cr Cl <80 m L/min). Free fraction of levetiracetam is not affected by hepatic impairment. Titrate slowly to reduce CNS side effects (somnolence, dizziness). Abrupt discontinuation may increase seizure frequency. Available in immediate-release tablets.
Diphenylan Sodium (phenytoin sodium) is a hydantoin anticonvulsant used for generalized tonic-clonic and complex partial seizures. It exhibits zero-order kinetics at therapeutic levels; small dose increases can cause disproportionate toxicity. Monitor for nystagmus, ataxia, and mental status changes as early signs of toxicity. Due to high protein binding (90%), hypoalbuminemia or uremia increases free fraction—adjust doses based on free phenytoin levels. Can cause folate deficiency, megaloblastic anemia, and bone density loss. Gingival hyperplasia occurs in 40% of patients; meticulous oral hygiene can reduce severity. Dosing must be individualized with therapeutic range 10-20 mg/L total (1-2 mg/L free). Intravenous loading requires cardiac monitoring due to risk of bradycardia and hypotension; avoid IM use due to crystallization and erratic absorption.
Take SPRITAM exactly as prescribed; do not stop suddenly.,May cause dizziness or drowsiness; avoid driving until effects are known.,Monitor for mood changes, depression, or suicidal thoughts.,Report any skin rash or signs of allergic reaction immediately.,Use reliable contraception if applicable (no known major interaction with hormonal contraceptives).,Swallow tablets whole; do not crush or chew.,Store at room temperature, away from moisture.
Take exactly as prescribed; do not stop abruptly as withdrawal can trigger seizures.,Avoid alcohol and grapefruit juice; they can affect drug levels and increase side effects.,Practice good oral hygiene with regular brushing and flossing to prevent gum overgrowth.,Report any rash, fever, sore throat, or easy bruising immediately—these may signal serious blood disorders.,Use non-hormonal contraception if on birth control; phenytoin reduces efficacy of oral contraceptives.,May cause dizziness or drowsiness; avoid driving until you know how you react.,Wear a medical alert bracelet if you have epilepsy.,Do not take antacids within 2 hours of phenytoin.,Regular blood tests are needed to monitor drug levels and liver function.,If you become pregnant, discuss with your doctor immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SPRITAM vs DIPHENYLAN SODIUM, answered by our medical review team.
SPRITAM is a Antiepileptic that works by Spritam is a levetiracetam formulation; levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A) to modulate neurotransmitter release, reducing neuronal excitability.. DIPHENYLAN SODIUM is a Antiepileptic that works by Phenytoin, the active component, stabilizes neuronal membranes by promoting sodium efflux and inhibiting sodium influx, thereby limiting the spread of seizure activity. It also reduces voltage-gated sodium channel activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SPRITAM and DIPHENYLAN SODIUM depend on the specific clinical indication. These are both Antiepileptic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SPRITAM is: SPRITAM is not a standard formulation; levetiracetam immediate-release: 500 mg PO BID, titrated to 1000 mg PO BID (max 1500 mg PO BID). For extended-release (Keppra XR): 1000 mg PO once daily, titrated to 2000 mg PO once daily.. The standard adult dose of DIPHENYLAN SODIUM is: 100 mg orally every 8 hours. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SPRITAM and DIPHENYLAN SODIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SPRITAM is classified as Category C. Spritam (levetiracetam) is classified as Pregnancy Category C. In the first trimester, there is an increased risk of major congenital malformations, including neural tube defects, . DIPHENYLAN SODIUM is classified as Category C. First trimester: Increased risk of major congenital malformations including neural tube defects, cleft palate, and congenital heart defects. Second and third trimesters: Risks of b. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.